Finally, our multivariate analysis showed that ApoA‐I is the best prognostic biomarker (reduction vs. elevation, HR, 2.27; 95% CI, 1.11–4.61; p = 0.034) to predict the outcomes of NPC patients treated with anti‐PD‐1 therapy. Here, APOA1 is linked to nasopharyngeal carcinoma.